Keywords
Cardiologia
Inibidores do Transportador 2 de Sódio-Glicose
dapagliflozina
tratamento
medicina
Insuficiência cardíaca
How to Cite
Abstract
Heart failure is a clinical syndrome in which the heart is unable to pump blood adequately to meet the body's demands, resulting from structural or functional cardiac alterations, manifested by symptoms and signs resulting from reduced cardiac output and/or increased filling pressures, both at rest and during exercise. Most cases are associated with low cardiac output, but conditions such as anemia, thyrotoxicosis, arteriovenous fistulas, and beriberi can lead to high-output HF. This article is an integrative bibliographical research, with a descriptive and explanatory nature. To conduct the study, the following guiding question was defined: "What is the Therapeutic Action of Sodium-Glucose Transporter 2 Inhibitors in Congestive Heart Failure?". The literature search was performed by surveying scientific productions, using databases available in the Virtual Health Library (VHL): Latin American and Caribbean Literature in Health Sciences (LILACS) and USA National Library of Medicine (MEDLINE/PubMed). Only publications in the form of scientific articles were considered. In this context, studies have indicated that dapagliflozin is effective and well tolerated, including in combination with diuretics such as furosemide, improving symptoms without the need for dose adjustments. Another substudy revealed that 27% of patients hospitalized for acute heart failure met the criteria for dapagliflozin use, with favorable results in reducing cardiovascular mortality and readmissions. Thus, it is concluded that the studies presented reinforce the relevance of sodium-glucose cotransporter type 2 inhibitors (SGLT2i), such as dapagliflozin and sotagliflozin, in the management of heart failure. Dapagliflozin has demonstrated significant benefits in patients with reduced ejection fraction, including reduced cardiovascular mortality, hospitalizations, and improvement of symptoms, even in combination with diuretics.
Keywords: Congestive Heart Failure, Treatment, Sodium-Glucose Transporter 2 Inhibitors.
References
CALDAS, Marcia Azevedo et al. Dapagliflozina no tratamento da insuficiência cardíaca com fração de ejeção reduzida: relato de caso. Revista Científica da Faculdade de Medicina de Campos, v. 17, n. 2, p. 60-65, 2022.
CARVALHO, Pedro EP et al. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clinical Research in Cardiology, v. 112, n. 8, p. 1044-1055, 2023.
COMITÊ COORDENADOR DA DIRETRIZ DE INSUFICIÊNCIA CARDÍACA. Diretriz brasileira de insuficiência cardíaca crônica e aguda. Arquivos Brasileiros de Cardiologia, v. 111, n. 3, p. 436-539, 2018.
GONZÁLEZ, Verónica. Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura. Revista uruguaya de cardiología, v. 36, n. 2, 2021.
KARUNAKARAN, Anandakumar et al. Analytical method development and validation for the estimation of Furosemide an anti-diuretic in Furosemide injection diluted with normal saline in presence of impurities by RP-HPLC. Brazilian Journal of Biological Sciences, v. 8, n. 18, p. 35-56, 2021.
MENDES, K. D. S.; SILVEIRA, R. C.; GALVÃO, C. M. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008.
NAVARRO-SOLANO, Jonatan; CHEN-KU, Chih Hao. Efecto terapéutico de los inhibidores del cotransportador sodio-glucosa tipo 2 en la insuficiencia cardiaca aguda. Acta Médica Costarricense, v. 65, n. 4, p. 173-180, 2023.
RIVERA-TOQUICA, Alex et al. Adherence to treatment guidelines in ambulatory heart failure patients with reduced ejection fraction in a Latin-American country: observational study of the Colombian heart failure registry (RECOLFACA). Cardiology, v. 149, n. 3, p. 228-236, 2024.
SETUBAL, Natasha Sartin; MARINI, Danyelle Cristine. A UTILIZAÇÃO DOS INIBIDORES DOS CO-TRANSPORTADORES DE SÓDIO-GLICOSE 2 NO TRATAMENTO DE PACIENTES COM INSUFICIÊNCIA CARDÍACA CONGESTIVA E SUA RELAÇÃO COM O AUMENTO DA EXPECTATIVA DE VIDA. Brasília Med, v. 61, p. 1-7, 2024.
URREA, Miguel Valverde. La FDA aprueba el uso de la sotagliflozina para prevenir la insuficiencia cardíaca en pacientes con diabetes. farmacología y terapéutica, 2023.
VILLARREAL, Daniel et al. Sodium-glucose cotransporter 2 inhibitors in frail patients with heart failure: clinical experience of a heart failure unit. Drugs & Aging, v. 40, n. 3, p. 293-299, 2023.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Nataly Maria Bezerra de Luna, Talita Queiroz Ferraz, Katryene Rochelly de Oliveira Cunha, Flávia Luana Lopes Tenório, Antonio Claudio Rocha Mesquita Formiga, Ana Maria Marinho Diniz, Tatiane Rairene de Moraes Costa, Letícia de Figueiredo Tavares, Daniel Galdino de Araújo Pereira, Mariana Cabral Menezes Domingues, Kelner Araújo de Vasconcelos, Matheus Augusto Albuquerque Costa